Optimizing melasma management with topical tranexamic acid: an expert consensus
Regulation of GSK3/Nrf2 signaling pathway modulated erastin-induced ferroptosis in breast cancer
More people who received semaglutide lost at least 5% of their starting body weight compared to those who received a placebo (86% vs 32%)
Lapaz AM, Yoshida CHP, Gorni PH, Freitas-Silva L, Arajo TO, Ribeiro C
Semaglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist, has demonstrated neuroprotective effects in preclinical studies 13 , including reducing -synuclein accumulation, attenuating lipid peroxidation and neuroinflammation, and supporting dopaminergic neuron survival 14,15
Sarkar S, Gough B, Raymick J, Beaudoin MA, Ali SF, Virmani A, Binienda ZK (2015) Histopathological and electrophysiological indices of rotenone-evoked dopaminergic toxicity: neuroprotective effects of acetyl-l-carnitine